Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070184 · ClinicalTrials.gov registry record · Phase 2
Race, Natriuretic Peptides and Physiological Perturbations
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03070184 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 80 participants.
The verdict
NCT03070184, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of the study is to understand the origins of differential response to beta-blockers in African-Americans and may provide insight regarding racial differences in cardiovascular risk.
Interventions
- OTHER Exercise capacity VO2 max determination
- DIETARY_SUPPLEMENT Standardized meals
- OTHER Exercise challenge
- DRUG Metoprolol Succinate ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-04-30 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070184
The ClinicalTrials.gov registry entry for NCT03070184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Exercise capacity VO2 max determination is the first listed.
NCT03070184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03070184 about?
NCT03070184 is a clinical study titled "Race, Natriuretic Peptides and Physiological Perturbations". The purpose of the study is to understand the origins of differential response to beta-blockers in African-Americans and may provide insight regarding racial differences in cardiovascular risk.
What is the current status of trial NCT03070184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-04-30. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT03070184?
The interventions under investigation include: Exercise capacity VO2 max determination (OTHER), Standardized meals (DIETARY_SUPPLEMENT), Exercise challenge (OTHER), Metoprolol Succinate ER (DRUG).
Who is sponsoring clinical trial NCT03070184?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.